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9:00 
~'7"3--3-] Thrombolysis After Resuscitation in Acute 
Myocardia l  Infarction 
Rudolf Schlale, J0rg Rustige, Udo Burczyk, Attain Koch, Dietdch Harmjenz, 
Ulrich Tebbe, Jochen Senges, for the ALKK Study Group. Herzzentmm 
Ludwigshalen, ZMBT Heidelberg; Germany 
Cardiopulmonary resuscitation (CPR) is often regarded as a relative con- 
tralndication to thrombelytlc therapy in AMI. We present results about the 
usage, safety and efficacy of iv@sis in CPR pts with AMI. "The 60-Minutes 
Myocardial Infarction Project" is an open German multicenter study, which 
registered all transmural AMI in 136 hospitals prospectively over 27 months. 
From a total of 14.980 AMI, 681 pts (4.5°/=) received CPR with chest com- 
pressions (mean age 64 4-13 yrs, 73% male, 53% anterior wall MI). 
Results: 45% of all CPR pte received iv-thrombolysis. CPR pts with lysla 
had a lower intrahospital mortality, despite more bleeding complications. In 
a multivariate analysis adjusting for 14 risk factors (including age), tysis was 
independently associated with a lower mortality (odds ratio 0.6, 95%-CI 0,4- 
0.9), except for the subgroup of pts with a left bundle branch block (12%), 
who did not benefit from tysis (OR 3.7, 95%-CI 0.9-15). 
CPR ht AMI All CPR Lysla No tysis p 
(n = 6B1) (n = 308) (n - 373) 
Hospllal mortality 56% 48% 62% <0.001 
Hemorrhage & transfusion 3.4% 6.5% 0.8% <0.001 
Conclusions: The outcome in nonrandomized CPR pts with AMI receiving 
thrombelysis is better despite more bleeding complications, The improved 
outcome is most likely a lysis effect, not only a selection bias. 
9:15 
~ Predictom of  Artery la tency Maintained Infarct After 
Primary Angloplesty in High Risk Patients In PAMI-2 
Keith H. Benzuly, William W. O'Neill, Bruce Brodie, John Griffin, 
Thomas Shimshak, Denise E. Jones, Madann Graham, Uoudmfla Mitina, 
Cindy L Grines. William Beaumont Hospital, Royal Oak, Michigan 
Sustaloed ropadusion is an important predictor of long term prognosis follow- 
ing acute MI. To determine predictors of sustained infarct artery (IRA) patency 
after primary PTCA, we performed a blinded core lab analysis of 298 high 
risk pts who underwent protocol re-catheterizatior~ prior to discharge in the 
PAMI-2 study. Pdmary PTCA was successful (IRA < 50°/= residual stenosis 
end TIMI 2-3 flow) in 95.8% of high-risk patients. 
ReCath TIMI flow P-value 
0-1 (n = 27) 2-3 (n = 271 )
ASA at home (%) 19.2 21.8 0.76 
Prior MI (%) 4.0 21.8 0.04 
MuItbessel Disease (%) 40.7 52.0 0.26 
Right coronary PTCA (%) 40.7 32.8 0.41 
Balloon Size (mm) 3.11 :t: 0.45 3.08 :t: 0.46 0.73 
Post PICA TIMI-3 (%) 92.6 90.8 0.75 
Residue1Stsnosls (mt'~n) 9.5.9 :E 18.3 22.7 ~ 11.9 0.38 
Post PTCA Dissection !%) 48.2 24.6 (N = 264) 0.009 
Acute eje~. ion fraction, infarct zone wall motion, presence of thrombus, 
use of lytlcs ov balloon pump, age, diabetes, smoking, hypertension and 
hyperlipldemia were not predictive of TIMI flow at recath. 
Conclusion: Absence of prior myocardial infarction or the presence of 
dissection following PTCA in high risk MI pte is predictive of rcocclusion on the 
pre-discharge angiogram. Aggressive treatment of dissection complicating 
PTCA of acute MI may improve outcome. 
9:30 
~';73---'~ Antlplatelet vs, Antlcoagulat lon Treatment Alter 
Intracoronsry Palmaz-Schetz Stent Pla~emest in 
Acute Myocardial Infarction ~ A Prospective 
Randomized TrIM 
Hanna Walter, Franz-Josef Neumann, Gert Richardt, Eckhan:l Aft, 
Claus Schmitt, Rudolf Blesioi, Helmut SchQhlan, Marlin Hadamiizky, 
Eva Zdzmann, Albert Sch0mlg. 1. Medizinische Klinik, Klinikum rechts der 
Isar, Technische Univeralt~f Munich, Germany 
A recent study has demonstrated the feasibility and safety of intracoronary 
stent placement in acute myocardial infarction (AMI). Aim of our study was 
the comparison of two different antithrombetio regiments after stesting In AMI. 
Within a prospective randomized trial an anticoagulalion pmtocel (espldn 100 
mg btd+ phenprocoumon I.v.-heparin until a target INR of 3.5) was compared 
with an antiplatatst protocol (aspirin 100 mg bid + ticlopldine 250 mg bid). 
Between October 1, 1994, and August 31, 1995, 105 randomized patients 
had slant placement in uncomplicated AMI. Patients with cardiugenio shock 
or the need of mechanical ventilation were excluded from randomlaaticn. So 
far 54 patients are randomized for anticoagulation, 51 for antiplatelat protocol. 
The randomization will be completed October 1,1995. Cardiac events (death, 
myocardial minfarction, stant occlusion, CABG, repeat PTCA) and bleeding 
events requiring transfusion or surgery, or impairing organ function, and local 
groin complications are assessed. Reangiography is performed two weeks 
and 6 months after the intervention. Angiographio data are evaluated by an 
automated edge detection method. 
Analysis of the two treatment groups for clinical events and engiugraphic 
outcome during a 30 day and 6 month follow up period will be presented. 
9:45 
~ ' ~  Stsntlng for Acute Myocardial Infarction: The Earty 
United States Mull icenter Experience 
Steven R. Steinhubl, David J. Molitemo, Paul S. Teirstein, Erminia 
M. Guameri, Frank V. Aguirre, James J. Fergucon, Emerson C. Perin, 
Nell Strickman, Dean Kerelakes. James E. Tcheng, Stevan G. Ellis, Eric 
J. Topoi. The Cleveland Clinic Fou~n,  C;eveland, OH 
Plaque fissuring and rupture, with resultant thrombosis, is the etiology of 
acute MI in nearly all patients with ST elevation. Primary and rescue an- 
gioplasty of the infarct-related i~rtery not infreqt,ently results in a localized 
or propagated intimal dissection, and in come patL=,~, ts rethrombesla of tho 
vessel. Empirically, slanting was thought to be contrai;x, cated fur acute MI 
because of the propensity for thrombosis. 
Methods: With contemporary opLimal slant deployment techniques, whicd 
appear to reduce subanute thrombosis in elective intewentions, thla app!ica- 
tion in acute MI was explored at 6 U.S. centare involving 44 patients. 
Resu~: Direct intervention was performed in 68% of patients and as 
rescue after failed thrombotysLs in 32%. Slants were placed seconda~ to 
dissection in 76=, sub-optimal results in 19% and as pdmary treatment in 
5%. More than 1 stent was placed in 27%. The mfemge vessel size was 
3.22 ram, and the average maximal inflation pressure was 13.8 arm. Pert- 
procedural medications included heparin (100°/=), aspirin (100%), urokinase 
(27%), ReoPm (19%), T'clid (19°/,) and Persantine (5%). Initial procedural 
success rate was 95%. 30-day outcome included 2% re-PTCA, 5% CABG 
a,'~d 7"/, morLali~. Tv,~O of these adverse outcomes (4.5% of total cohort) were 
secondary to subacuta stent thrombosis. 
Conclusion: Using current optimal stent deployment techniques with anti- 
platelet and anti-thrombotic therapy, intracoronary slants are a promising 
therapy in evolving MI. True dsk and cost-benerd assessment will require 
prospective randomized trials. 
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8:30 
I " ~  Long-Term Calcium-Channel Blockade Causes Left 
Ventricular Dilation in Asymptomatic Patients With 
Chronic Infarction 
Petor Gaudmn, Ingdd Kugter, Kai Hu, C. Eilles 1, Georg Ertl. Departmanfof 
Medicine II Mannheim, University of Heidelberg; 1Regeosburg, Germany 
Calciumchannel t~l~ker (CCB) may precipitate adveme events in patients 
with severe left ventdcular (LV) dysfunction after myocardial infarction (Mi). LV 
dilation precedes LV dysfunction and is an independent predictor of adveme 
events and mortality in patients after ML We tested that the new-generation 
CCB niscldipine (Ntso), a potent vacodilatsr, may prevent LV dilation (remod- 
eling) after mild asymptomatic LV-dysfunction following moderate ML In a 
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prospective double-bllnd study, patients were randomized to placebo (P) or 
low-done (10 rag/pay) Niea in the fhet weed, after Mi and reexamined 2hem, 
~. 6 and 18 months later. Exclusions were clinical heart faifure, uncontrolled 
hypertension and angina pactoris. At baseline (mean 4- sd), age was 56 4- 
8 and 56 4- ¢ yearn, infarct size (biplane cinsanglugraphy) 16 =1= 14 and 12 
4.12% o~ I v radmnudlde LV ejection fraction (EF) 45 4.11 m~l 44 4.15°/=, 
end-dlssk,:, volume (gated SPEC") 155 4. 29 and 142 4. 26 ml, wedge 
pressure (Swan-Ganz c~t~',tsr) '~' -~ 4 and 12 4. 5 mmHg m P (n = 20) 
and Nlso (n = 15), rasl~ ~::t, ~, Progressive LV dilation ocouwed with Niso 
(ANOVA p ,, 0.521) but no', :;, ~'i i~(T, Jre;'p<0.05vs.6monthe;1"p<0.05 
vs. P). 
Thus, even eaw-ganeration vasodilating COB such as nisoldlpine may be 
conlreindiceted even at low dose in patients with mild LV dysfunction. 
8:45 
J ' -~- - '~ Effect o f  Amlodlpine on Tolerance Exercise 8nd 
Quality o f  Life In Mild-To-Moderate Heart Failure 
With Syatoli¢ Dysfunction 
James E. Udaissn, C. Andrew DeAbate, Nampam Vi]ay, Stovan Chryeanto 
Kdshan Goyle, !wing Loh, Joel SkJar. William Smith. Marvin A. Konstam and 
the Amiodipine Exercise Trial Group. Tufts.New England Med Ctr,, Boston, 
MA 
We assessed the effect and safety of adjuvant reatment with amiodiplse 
(Amlo) on exercise tolerance and quality of life (QOL) in 152 patients with 
mild-to-modereta heart failure (59% NYHA class 2, 39% class 3) and LV 
systolic dysfunction (mean LV EF 23%). 192 such 10is with stable baseline 
exercise times were randomized in a double blind placebo controlled trial to 
Amlo (lflreted to 10 mg per day) or to placebo for 12 weeks. In 59% of lots, 
ischemic heart disease was the etiology of heart failure, and 83% of 10ts were 
on ACE inh~itors. QOL was measured with questionnaires including Living 
with Heart Failure (LHF), Health Perception, Alertness, and # of days in bed. 
Results (means): 
Amlo Plaoabo p 
Base Final Change Base Final Change 
Exercise time (sac) 545 608 +63 558 619 +61 0.5 
6 rain walk (yards) 399 401 +2 372 395 +23 0.2 
LV EF (%) 23 27 +4 23 26 +3 0.3 
LHF so0m 67 70 +3 70 73 +3 0.9 
Health pe~plton 49 53 +4 51 52 +1 0.09 
# bed dsys 0.4 0.6 +0.2 0.7 0.4 -0.3 0.2 
Alertness 86 90 -t-4 85 86 +1 0.1 
There were no differences between groups in change in NYHA class or 
symptoms, and, in contrast o prior sk.,d]es with calcium channel blockers, no 
difference in the need for increasing background heart failure therapy. Side 
effects were similar in the two groups, save for a small excess of mild edema 
in the Amio group. These data suggest that the addition of 10 mg Amlo to 
standard therapy in mild-to-modarato heart failure results in no Important 
changes in exercise time over 12 weeks of therapy, and Is also safe and well 
tolerated. 
9:00 
~ Circadian Rhythm and Sudden Death In Heart 
Failure: Results From PRAISE 
Peter Carson, Milton Preesler, Alan Miller, Susan Andemon, Robert Belkin, 
David Fdd, Gerald Neubarg, Chflstophsr O'Connor, John Werthaimer, 
Milton Packer for the PRAISE Investigators. VA Medical Center, 
Washington DC; Georgetown University Medical Centers, Washington, DG 
Previous analyses have indicated a temporal relation of acute cardiovas- 
cular events, particularly In the early morning due to neurohormonal (NH) 
activation. We postulated that the chronic NH stimulation in heart failure 
(HF) would produce an uniform pattern of sudden death (SD) events. There 
were 185 SD in '=RAISE with approximating time of death for 152 pts. We 
analyzed for unik.~.nlty using a chl-sqeare statistic end 4 hour intervals, The 
results showed significant non-uniform!ly (p = 0.01) with a P.M. peak for the 
entire cohort. When analyzing by HF etiology, ischemlc (I) pts circadian SD 
distribution differed from nonischemic (NI) (p = 0.001, with I pts showing the 
P,M, peak while NI pts did not. 
By treatment, he distribution of events did not significantly differ. Conclu- 
SS m~Vln dl lgl l ;  n .  1111 l~n,!lldtmd~ p l t l l~ l  wk'1~, n = I~ II~lem~ luztll1111 ~,  n .  10B 
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¢~lmlmml  czm~m blznll C~Im Irllm~l~ 
ston: In PRAISE, HF pts showed a non-uniformity of SD events with late 
affamnon peak. The presence of this peak in iashemfo but not nonlschemlo 
patients raises the hypothesis that these SO events were in large part is- 
chemic. An early A.M. peak suggesting a nourohormonal effect was not seen. 
Amlodipine treatment did not significantly alter the dlstn'bution of events. 
9:15 
~ Dissociation Between the Inotreplc and Systemic 
Effects o f  the Calcium Promoter BAY y 5959 In 
Patlents Wilh Heart Failure 
Michel F. Rousseau, Plee'e E. Maseart, Christian van Eyll, Jean Etienoe, 
Sylvle Ahn, Liviu Stoleru, Mariln Bomemann, Hubert Pouleur. Univars~ of 
Lnovain, Brussels, Belgium 
The effects of the calcium promoter BAY y 5959 (BAY) on LV function 
(angiogrephy + MiJlar) and systemic h ~ l c e  were studied in 20 
with severe heart failure (NYHA Ill-W, moan LVEF 17%, range 6-32%). 
Data were obtained before and after 20 rain infusion of BAY at 4 dose levels 
(1, 2, 3 and 4.5 p.g/kg/min; 5 pts per dose). Heart rate arKI LV end-diastolic 
pressure decreased at each dose level (average 85 to 75" bpm and 29.2 
to 24.9" mmHg) but the effects on the isovolumic indices of inotrepfo stats, 
cardiac index ((31) and systemic vascular resistance (SVR) vailed mere with 
dose. 
Dose &CI &$VR ~dP/dt Max &(dP/dl)/DP40 
(t~g/l<g/min) (%) (%) (%) (%) 
1 -0:1:8 54-7 0-4-5 15=E4 = 
2 23±13 = -14:E9" 14-;-6" 19:1=14 
3 11 4-6" -7 =b 11 25-1-10" 44-1-17" 
4.5 8:E13 5:~13 56-*-10 °= 72:1:12 'o 
°p < 0.05 "p  < 0.001 mean ~ SEM 
Mean systolic stress was unchanged and LVEF improved (in absolute 
values) by 2.b~ro ", 4.4%*, 6.6%* and 12,8%" at the 1, 2, 3 and 4.5 doses, 
respectively. Relaxation rate was unaffected and QTc was prolonged but 
no prcerrhythmia was detected. Thus, in this study, the optimal response, 
combining bredysardia, reduced prelead and improved systemic perfusion is 
achieved around 2 p.g/kg/min, and BAY appears premising for intravenous 
use in severe pump failure. 
9:30 
_Dose and Circadian Dependent Autonomic 
HeapOnea tO Veaodllation With Amlodlplne In 
uongeat ive Heart Failure 
Philip F. Btnldey, Enrfco Nunziate, Patricia S. Hatton, Robert J. Cod),. The 
Ohio State University, Columbus, Ohio 
The influence of the calcium channel blocker amfodipine [Atoll on the auto- 
nomlc imbalance characteristic in congestive heart failure [CHF] Is currently 
unknown. We therefore assessed diurnal patfams of autonomic tone using 
spectral analysis Of heart rata variability [I-IRV] performed on each hour of 
Holler recordings obtained on 51 patients with CHF at baseline [Ba] and after 
3 months of treatmnnt ['rr] with either placebo [P] or 5 or 10 mg of Ami in ad- 
dition to standard therapy. The diurnal pattom of parasympatheticetiy [para] 
gevemed high frequency It-IF] HRV did not differ ~mong groups at baseline; 
however, 10 mg, but not 5 mg of Aml produced a algnificsntly [ANOVA p 
= 0.03] different diurnal pattern of HF HRV compared to P. This ditference 
resulted from an increase in HF HRV [heatS/min]~/Hzl] between 3 and 8 AM 
with 10 mg Aml [Ba: 2.83 x 10 -s 4. 0.48 x 10 --4 vs Tr: 3.46 x 10 -'q .4- 0.60 
x 10 "4] which significantly differed [ANOVA p = 0.02] from a decrease seen 
in P [Be: 3.21 x 10 -s 4- 0.43 x 10-4 vs Tr: 2.84 x 10 4 4- 0,38 x 10-4]. 
However, between 9 PM and 2 AM, 10 rog Aml decreased HF HRV [Ba: 3.08 
x 10 -s 4- 0.50 x 10-4 vs Tr: 2,54 x 10 "a 4- 0.43 x 10 "4] which s/gnifisantly 
differed [ANOVA p = 0.04] from an increase noted with P [IZA: 3.27 x 10 -s 4- 
0.37 x 10 -4 vs Tr: 3.60 x 10 -s 4- 0.39 x 10-4]. Differences from P were not 
seen at other times. Therefore, 1. Only 10 mg daily Ami significantly alters 
autonomic tone in CHF; 2. Ami assodafad changes in pare tone vary with 
time of day. The augmentation of parasympathetic tone between 3 and 8 AM 
may be protective at this time in which vulnerability to vantricular arrhythmias 
is typically increased. 
